阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALNY 阿尔尼拉姆制药公司

休市中 05-15 16:00:00 EDT

286.98

-6.47

-2.20%

盘后289.00

+2.02+0.70%

19:34 EDT

最高298.00	最低286.76	成交量114.96万
今开294.78	昨收293.45	日振幅3.83%
总市值382.91亿	流通市值362.04亿	总股本1.33亿
成交额3.32亿	换手率0.91%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"阿尔尼拉姆制药公司","latestPrice":286.98,"timestamp":1778875200000,"preClose":293.45,"halted":0,"volume":1149625,"hourTrading":{"tag":"盘后","latestPrice":289,"preClose":286.98,"latestTime":"19:34 EDT","volume":126237,"amount":36228046.5729,"timestamp":1778888095948,"change":2.02,"changeRate":0.007039,"amplitude":0.007039},"delay":0,"changeRate":-0.02204804907139196,"floatShares":126154848,"shares":133427910,"eps":4.0295005,"marketStatus":"休市中","change":-6.47,"latestTime":"05-15 16:00:00 EDT","open":294.78,"high":297.9999,"low":286.76,"amount":332012562.21875,"amplitude":0.038303,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.0295005,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":293.45,"preHourTrading":{"tag":"盘前","latestPrice":293.21,"preClose":293.45,"latestTime":"09:29 EDT","volume":733,"amount":215023.54158,"timestamp":1778851783146,"change":-0.24,"changeRate":-0.000818,"amplitude":0.034637},"postHourTrading":{"tag":"盘后","latestPrice":289,"preClose":286.98,"latestTime":"19:34 EDT","volume":126237,"amount":36228046.5729,"timestamp":1778888095948,"change":2.02,"changeRate":0.007039,"amplitude":0.007039},"volumeRatio":1.1716045387899177,"impliedVol":0.3425,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/ALNY/tweets","defaultTab":"tweets","newsList":[{"id":"1118719716","title":"心衰2026大会发布新数据分析：Vutrisiran作为一线治疗方案在ATTR-CM患者群体中展现强劲且一致的临床获益，包括高疾病负担患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1118719716","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118719716?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:30","pubTimestamp":1778567419,"startTime":"0","endTime":"0","summary":"在近期举行的“心衰2026”大会上公布的最新数据分析显示，Vutrisiran作为一线治疗选择，在转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）患者群体中，展现出强劲且一致的临床获益。这一积极结果覆盖了包括高疾病负担在内的广泛患者亚组，为该疗法的应用前景提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","ALNY","BK4548","LU0889565916.HKD","BK4139","LU0320765992.SGD","BK4585","BK4588","LU0114720955.EUR","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163333507","title":"阿尔尼拉姆制药公司将于2026年心力衰竭大会公布新分析，凸显Vutrisiran在ATTR-CM中一致的临床特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1163333507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163333507?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:30","pubTimestamp":1777897826,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（Alnylam Pharmaceuticals）计划在2026年心力衰竭大会上展示最新分析数据，这些数据进一步证实了其在研药物Vutrisiran用于转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）治疗时展现出的稳定临床效果。\n此次公布的分析结果将强化Vutrisiran的临床价值，为患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4588","BK4548","ALNY","LU0889565916.HKD","LU0320765992.SGD","BK4585","LU0109394709.USD","BK4139","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154504008","title":"异动解读 | 阿尔尼拉姆制药公司盘前大涨6.25%，受财报及业务进展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1154504008","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154504008?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:07","pubTimestamp":1777550837,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司（ALNY）今日盘前股价大幅上涨6.25%，引起了市场的广泛关注。消息面上，公司于盘前披露了2026年第一季度财务业绩报告，并重点展示了在报告期内取得的多项关键业务进展。这份积极的财报和业务更新，增强了投资者对公司未来发展的信心，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100877819","title":"阿尔尼拉姆制药公司公布2026年第一季度财报及近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100877819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100877819?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:01","pubTimestamp":1777550479,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司近日披露了2026年第一季度财务业绩报告，同时重点展示了公司在报告期内取得的多项关键业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","LU0109394709.USD","BK4585","BK4139","LU0114720955.EUR","BK4548","LU0889565916.HKD","LU0320765992.SGD","LU0882574055.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147790578","title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增90.11%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1147790578","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147790578?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:35","pubTimestamp":1776908112,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将于2026年04月30日（盘前）发布最新季度财报，市场关注收入高增与盈利质量的协调性。市场一致预期显示，本季度阿尔尼拉姆制药公司营收预计为11.14亿美元，同比增长90.11%；调整后每股收益预计为0.93美元，同比增长192.63%；公司未披露本季度的毛利率与净利润或净利率的明确预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增90.11%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154632206","title":"杰富瑞对阿尔尼拉姆制药公司启动覆盖，给予持有评级，目标价330美元，此前为买入评级及522美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1154632206","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154632206?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:47","pubTimestamp":1773647233,"startTime":"0","endTime":"0","summary":"杰富瑞集团近日宣布，对阿尔尼拉姆制药公司启动研究覆盖，并给予其股票“持有”评级。与此同时，该机构设定了330美元的目标股价。\n这一评级与之前机构给予的“买入”评级形成对比，且目标价也从先前的高位522美元大幅下调至330美元。此番调整反映了分析师对公司未来前景的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","BK4139","BK4548","LU0320765992.SGD","LU0882574055.USD","LU0109394709.USD","BK4588","LU0114720955.EUR","ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177542029","title":"Tenaya Therapeutics与Alnylam Pharmaceuticals达成研究合作，共同探索心血管疾病治疗新靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1177542029","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177542029?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:36","pubTimestamp":1772717783,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc（简称Tenaya）已与Alnylam Pharmaceuticals（简称Alnylam）正式签署一项研究合作协议。双方将携手致力于识别并验证针对心血管疾病治疗的新型遗传靶点，旨在推动相关疗法研发取得突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","LU0320765992.SGD","BK4588","LU0109394709.USD","LU0889565916.HKD","ALNY","BK4548","BK4539","LU0882574055.USD","BK4585","BK4139","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137928746","title":"阿尔尼拉姆制药公司：旗下药物Amvuttra获加拿大药品管理局公共报销积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1137928746","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137928746?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:03","pubTimestamp":1772456597,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司近日迎来重大利好消息。加拿大负责药品评估与报销建议的关键机构——加拿大药品管理局，已对其创新药物Amvuttra给出了积极的公共报销推荐意见。\n这一推荐意味着，符合特定条件的加拿大患者未来有望通过公共医保系统获得Amvuttra的治疗，从而显著减轻经济负担。此举不仅提升了该药物的可及性，也为阿尔尼拉姆制药公司在加拿大市场的拓展注入了强劲动力。\nAmvuttra是一种基于RNA干扰技术的治疗药物，用于治疗遗传性转甲状腺素蛋白淀粉样变性伴多发性神经病。获得官方机构的报销推荐，是创新药物成功商业化并惠及更多患者的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","ALNY","BK4548","LU0109394709.USD","LU0114720955.EUR","LU0882574055.USD","LU0320765992.SGD","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128963715","title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1128963715","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128963715?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:16","pubTimestamp":1770257799,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将于2026年02月12日发布最新季度财报，市场关注收入与盈利改善的延续性，并聚焦核心产品组合的放量表现及费用效率变化。市场一致预期显示，本季度阿尔尼拉姆制药公司收入预计为11.73亿美元，同比增长100.90%；调整后每股收益预计为1.16美元，同比增长185.85%；息税前利润预计为2.04亿美元，同比增长321.65%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜阿尔尼拉姆制药公司本季度营收预计增100.90%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194639707","title":"阿尔尼拉姆制药公司第四季度Amvuttra与Onpattro净产品收入分别约为8.27亿美元及3200万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194639707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194639707?lang=zh_cn&edition=full","pubTime":"2026-01-12 06:11","pubTimestamp":1768169473,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司最新财务数据显示，其核心药物Amvuttra在第四季度展现出强劲的市场表现，净产品收入达到约8.27亿美元。与此同时，另一款重要产品Onpattro同期净产品收入约为3200万美元。这两款疗法的销售表现共同反映了公司在特定治疗领域的市场渗透力和商业执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0320765992.SGD","LU0114720955.EUR","LU0882574055.USD","LU0889565916.HKD","ALNY","BK4139","BK4548","BK4585","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601944808","title":"阿里拉姆制药涨0.58% 股价突破400美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2601944808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601944808?lang=zh_cn&edition=full","pubTime":"2026-01-07 02:12","pubTimestamp":1767723140,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日02时12分，阿里拉姆制药股票出现波动，股价急速拉升0.58%。截至发稿，该股报400.12美元/股，成交量64.8612万股，换手率0.49%，振幅3.92%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.08倍。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.76%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107021220a6fb4b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107021220a6fb4b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4575","LU1048588211.SGD","LU1051768304.USD","LU0918141887.USD","BK4534","LU0348816934.USD","LU1046422090.SGD","LU0109394709.USD","LU1235294995.USD","LU1003077747.HKD","LU0949170772.SGD","LU1769817096.USD","BK4533","LU2226246903.HKD","LU0882574055.USD","LU0918141705.HKD","BK4220","LU0661504455.SGD","LU0880133367.SGD","BK4505","BK4587","BK4535","LU1769817179.HKD","LU1267930227.SGD","BK4122","BK4543","BK4504","LU0047713382.USD","BK4502","LU2148611432.USD","BK4554","LU1152091168.USD","BK4538","LU0348814723.USD","BK4531","LU0106959298.USD","LU1688375341.USD","LU1242518931.SGD","LU0067412154.USD","BK4527","LU0328353924.USD","LU1051769294.HKD","LU1823568750.SGD","BK4558","BK4526","BK4565","LU0114720955.EUR","BK4139","LU0072913022.USD","LU0553294199.USD","BK4579","LU0797268264.HKD","BK4614","BK4503","LU0651947912.USD","LU0251143458.SGD","BK4585","LU1048596156.SGD","LU0320765992.SGD","LU1046421795.USD","BK4581","LU1880383366.USD","IE00BF5LJ272.USD","LU0128525689.USD","LU0545039389.USD","BK4548","LU0072462343.USD","BK4588","LU1515016050.SGD","LU0651946864.USD","LU1152091754.HKD","LU1008478684.HKD","LU1282648689.USD","LU0501845795.SGD","LU0310800965.SGD","LU0979878070.USD","BK4524","BK4607","LU0052756011.USD","LU1242518857.USD","LU1105468828.SGD","LU0889565916.HKD","ALBmain","ALNY","LU0821914370.USD","IE00B0JY6N72.USD","LU0738911758.USD","IE00BFMHRM44.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1141535458","title":"Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1141535458","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141535458?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:23","pubTimestamp":1766060587,"startTime":"0","endTime":"0","summary":"12月18日（路透社）- PeptiDream Inc <4587.T>::* Peptidream与阿尔尼拉姆制药公司宣布在siRNA结合物发现合作中取得关键里程碑，证明了肽配体介导的靶向siRNA输送到特定的肝外组织。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0109394709.USD","LU0882574055.USD","BK4585","LU0114720955.EUR","ALNY","BK4139","BK4548","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592285948","title":"阿里拉姆制药涨2.28% 股价突破400美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2592285948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592285948?lang=zh_cn&edition=full","pubTime":"2025-12-17 23:06","pubTimestamp":1765984007,"startTime":"0","endTime":"0","summary":"北京时间2025年12月17日23时06分，阿里拉姆制药股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.36%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046421795.USD","LU0553294199.USD","LU1769817179.HKD","LU0328353924.USD","BK4527","LU1282648689.USD","BK4543","LU0320765992.SGD","LU1242518931.SGD","ALNY","LU0072913022.USD","BK4502","LU0348814723.USD","LU1003077747.HKD","LU1267930227.SGD","LU1769817096.USD","BK4535","BK4220","BK4558","LU0797268264.HKD","BK4614","LU0651947912.USD","LU0949170772.SGD","BK4503","IE00BF5LJ272.USD","LU0661504455.SGD","BK4587","LU0738911758.USD","BK4534","LU1235294995.USD","BK4579","LU1152091168.USD","LU1051768304.USD","LU0067412154.USD","LU0918141705.HKD","LU2148611432.USD","LU0052756011.USD","LU0882574055.USD","LU0651946864.USD","LU0128525689.USD","BK4588","LU0072462343.USD","LU0114720955.EUR","IE00B0JY6N72.USD","LU0348816934.USD","LU1046422090.SGD","BK4585","BK4548","ALBmain","LU0821914370.USD","LU0918141887.USD","BK4538","BK4607","LU1242518857.USD","LU0310800965.SGD","LU0106959298.USD","BK4533","LU0545039389.USD","LU0047713382.USD","BK4526","BK4505","IE00BFMHRM44.USD","BK4122","LU1515016050.SGD","LU0251143458.SGD","LU1823568750.SGD","BK4139","LU1051769294.HKD","LU1105468828.SGD","BK4531","LU2226246903.HKD","BK4565","LU1048588211.SGD","LU1048596156.SGD","BK4524","LU1880383366.USD","LU0501845795.SGD","BK4581","LU1152091754.HKD","LU0109394709.USD","LU1008478684.HKD","BK4554","LU0880133367.SGD","BK4575","LU0979878070.USD","LU1688375341.USD","LU0889565916.HKD","BK4504"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1119407729","title":"阿尔尼拉姆制药公司将投资2.5亿美元增强美国制造设施的酶连接平台以满足全球对RNAi治疗的日益增长的需求","url":"https://stock-news.laohu8.com/highlight/detail?id=1119407729","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119407729?lang=zh_cn&edition=full","pubTime":"2025-12-17 21:04","pubTimestamp":1765976640,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司将投资2.5亿美元，增加酶连接平台到美国制造设施，以应对全球对RNAi治疗日益增长的需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0882574055.USD","LU0114720955.EUR","BK4548","LU0109394709.USD","BK4585","ALNY","LU0889565916.HKD","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166333259","title":"纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1166333259","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166333259?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:21","pubTimestamp":1765588891,"startTime":"0","endTime":"0","summary":"12月12日（路透社）- 纳斯达克公司宣布：*纳斯达克公司 - 宣布纳斯达克100指数的重组，将于12月22日生效* 纳斯达克公司：六家公司将被添加到纳斯达克100指数* 纳斯达克公司：渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数* 纳斯达克公司：阿尔尼拉姆制药公司、FERROVIAL、INSMED、Monolithic Power Systems、希捷科技、西部数据将被添加到纳斯达克100指数。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124384867.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0056508442.USD","LU1496350502.SGD","LU0889565916.HKD","LU1670628061.USD","BK4009","LU1642822529.SGD","BK4548","LU0109391861.USD","LU2360107325.USD","LU0320765992.SGD","ON","BK4533","LU0006061336.USD","LU2360106780.USD","BK4588","LU2473716301.USD","CDW","LU0114720955.EUR","LU2089985449.USD","LU1861215975.USD","LU1854103824.USD","BIIB","BK4613","LU2272731782.SGD","LU1992135472.HKD","LU2322448791.USD","BK4170","LU1069347547.HKD","BK4512","IE00B19Z9P08.USD","LU2250418816.HKD","LU0672654240.SGD","LU0203345920.USD","LU0708995401.HKD","LU1035773651.USD","LU0320765059.SGD","LU1548497426.USD","LU1815336760.USD","LU1670627923.USD","LU1046421795.USD","BK4141","LU0353189680.USD","BK4202","LU1992135399.USD","LU1720051017.SGD","LU0476273544.USD","BK4139","LU0882574055.USD","LU1861220033.SGD","IE00B19Z9Z06.USD","LU1267930730.SGD","LU1823568750.SGD","IE00BFMHRM44.USD","LU1854104046.USD","GFS","LU1978683503.SGD","BK4532","ALNY","LU2360107168.USD","LU2087625088.SGD","LU0348723411.USD","BK4528","BK4504","BK4140","STX","BK4605","TTD","LU0234570918.USD","MPWR","LU0203347892.USD","LU2290526834.HKD","LU0353189763.USD","IE00B894F039.SGD","LU0823411888.USD","LU0274383776.USD","LU0957808578.USD","LU1235294995.USD","LULU","LU2357305700.SGD","LU0724618433.USD","LU0109394709.USD","LU1861214812.USD","LU2272731865.HKD","IE00BD6J9T35.USD","LU2272731600.USD","LU0081259029.USD","IE00BN0W2T93.GBP","LU2322448957.HKD","IE00BZ199S13.USD","LU2298322129.HKD","BK4585","LU1861219969.SGD","WDC","LU2931357623.SGD","LU1852331112.SGD","LU0444971666.USD","LU1720051108.HKD","BK4023","LU0444973449.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131212462","title":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1131212462","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131212462?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:09","pubTimestamp":1765588155,"startTime":"0","endTime":"0","summary":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0edbc198404a72334f079a67157af149","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0353189763.USD","LU0353189680.USD","STX","IE00B19Z9Z06.USD","LU2322448791.USD","LU0320765059.SGD","IE00BKPKM429.USD","LU2250418816.HKD","IE00BN0W2T93.GBP","LU2272731600.USD","BK4139","LU0314104364.USD","LU0708995401.HKD","LU0056508442.USD","IE00B64PRP62.GBP","IE00BD6J9T35.USD","LU1861220033.SGD","LU0109394709.USD","LU1267930730.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","LU0957808578.USD","IE00B894F039.SGD","LU1670628061.USD","LU0476273544.USD","BK4588","LU2095319765.USD","BK4141","LU0672654240.SGD","WDC","LU2360106780.USD","NDAQ","LU2322448957.HKD","SG9999014005.SGD","LU1861215975.USD","LU1815336760.USD","LU0320765992.SGD","LU1992135472.HKD","LU0889565916.HKD","LU1670627923.USD","LU1046421795.USD","LU1823568750.SGD","LU0109391861.USD","BK4512","LU1235294995.USD","LU2210149790.SGD","LU2360107168.USD","LU0114720955.EUR","LU0882574055.USD","LU1992135399.USD","LU0203347892.USD","LU2087625088.SGD","LU0203345920.USD","LU2473716301.USD","LU1642822529.SGD","BK4585","LU1035773651.USD","IE00B3QW5Z07.USD","BK4170","LU0053671581.USD","BK4112","LU1852331112.SGD","LU2210150020.SGD","BK4548","LU0444971666.USD","LU0274383776.USD","INSM","SG9999014039.USD","LU2272731865.HKD","MPWR","LU0444973449.USD","SG9999014013.SGD","LU1069347547.HKD","LU2089985449.USD","ALNY","IE00B19Z9P08.USD","LU0081259029.USD","IE00BGHQF748.EUR","LU0006061336.USD","LU2931357623.SGD","IE00BN0W2W23.USD","LU2272731782.SGD","LU2290526834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117266784","title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1117266784","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117266784?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:08","pubTimestamp":1765588106,"startTime":"0","endTime":"0","summary":"12月13日，纳斯达克公司宣布纳斯达克100指数成份股调整将于12月22日生效。6家公司即将被纳入纳斯达克100指数。分别是艾尼拉姆制药公司、费罗维亚集团、英斯梅德公司、单片电源系统公司、希捷科技控股有限公司和西部数据公司。而有6家被移出，百健公司（Biogen）CDW公司、格芯公司、露露乐蒙、安森美半导体和交易台公司（The Trade Desk）。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTD","BIIB","GFS","NDAQ","ALNY","WDC","STX","CDW","FER","ON","MPWR","LULU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137897631","title":"阿尔尼拉姆制药公司宣布董事会成员变更","url":"https://stock-news.laohu8.com/highlight/detail?id=1137897631","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137897631?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:17","pubTimestamp":1764767856,"startTime":"0","endTime":"0","summary":"12月3日 - 阿尔尼拉姆制药公司宣布董事会成员的变更。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","ALNY","BK4548","LU0889565916.HKD","BK4139","LU0320765992.SGD","BK4585","BK4588","LU0114720955.EUR","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516301361","title":"阿里拉姆制药盘中异动 股价大涨5.07%报249.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516301361?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:55","pubTimestamp":1740776141,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时55分，阿里拉姆制药股票出现波动，股价急速拉升5.07%。截至发稿，该股报249.13美元/股，成交量65.6826万股，换手率0.51%，振幅5.14%。机构评级方面，在所有34家参与评级的机构中，71%的券商给予买入建议，24%的券商给予持有建议，5%的券商给予卖出建议。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.72%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010455429896c845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010455429896c845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4587","BK4585","LU0310800965.SGD","BK4535","BK4579","BK4543","BK4558","BK4503","LU1152091168.USD","BK4581","BK4534","BK4607","LU0918141887.USD","LU1008478684.HKD","BK4588","LU0918141705.HKD","BK4220","LU1823568750.SGD","ALNY","BK4526","LU0821914370.USD","LU1048596156.SGD","LU0348814723.USD","BK4504","LU1688375341.USD","LU0067412154.USD","BK4505","LU0348816934.USD","LU0797268264.HKD","LU1282648689.USD","IE00BFMHRM44.USD","LU0251143458.SGD","LU1105468828.SGD","BK4524","BK4139","BK4548","LU1515016050.SGD","LU1046421795.USD","LU0501845795.SGD","BK4533","LU0651946864.USD","BK4527","LU0128525689.USD","BK4538","LU2226246903.HKD","LU1046422090.SGD","LU1051768304.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514776864","title":"HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514776864","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514776864?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Alnylam Pharmaceuticals(ALNY.US)评级，由买入调整至买入评级, 目标价由400.00美元调整至500.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALNY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0274},{"period":"1month","weight":-0.1392},{"period":"3month","weight":-0.0872},{"period":"6month","weight":-0.3611},{"period":"1year","weight":0.0126},{"period":"ytd","weight":-0.2783}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月。该公司是一家研发基于RNA或RNAi干涉为新型治疗手段的生物制药公司。RNAi是一种在生物体内细胞中自然产生的选择性沉默及调控表达的特定基因。由于许多疾病是因为特定基因的不适当活动引起的，通过RNAi对于基因的选择性沉默能力可以为治疗许多人类疾病提供一种新的途径。公司认为，通过RNAi原理工作的药物有潜力成为的一种新的药物分类，诸如小分子药物、蛋白质药物以及抗体药物等。通过已经建立RNAi的知识产权以及专业技术，公司正在开发一套生物化学方法以帮助公司建立一个系统，通过该系统可以研发改进RNAi对于各种疾病的治疗方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.002754},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.012836},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.021744},{"month":5,"riseRate":0.590909,"avgChangeRate":0.036059},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"阿尔尼拉姆制药公司","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿尔尼拉姆制药公司,ALNY,阿尔尼拉姆制药公司股票,阿尔尼拉姆制药公司股票老虎,阿尔尼拉姆制药公司股票老虎国际,阿尔尼拉姆制药公司行情,阿尔尼拉姆制药公司股票行情,阿尔尼拉姆制药公司股价,阿尔尼拉姆制药公司股市,阿尔尼拉姆制药公司股票价格,阿尔尼拉姆制药公司股票交易,阿尔尼拉姆制药公司股票购买,阿尔尼拉姆制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿尔尼拉姆制药公司(ALNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿尔尼拉姆制药公司(ALNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}